• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Dengue Fever Sept.2007 Dr.Wail Bajhmoum
 

Dengue Fever Sept.2007 Dr.Wail Bajhmoum

on

  • 1,017 views

 

Statistics

Views

Total Views
1,017
Views on SlideShare
1,017
Embed Views
0

Actions

Likes
0
Downloads
20
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Dengue Fever Sept.2007 Dr.Wail Bajhmoum Dengue Fever Sept.2007 Dr.Wail Bajhmoum Presentation Transcript

    • Kingdom of Saudi Arabia King Fahd Hospital Jeddah Internal Medical Department
    • Dengue Fever By:  Dr.wail Bajhmoum  Wednesday 21/5/2008 ; 16/5/1429
    • Background Frequency Race ; Sex and Age
    • Transmission Mortality/Morbidity Clinical Presentation
    • Treatment Our hospital statistic
    • Background Dengue fever–like illnesses were described in Chinese medical writings dating back to 265 AD. In 1789, Benjamin Rush, MD, published an account of a dengue fever epidemic that had occurred in Philadelphia in 1780.
    • The first epidemic of dengue hemorrhagic fever was described in Manila in 1953.
    • Frequency Dengue virus causes about 100 million cases of acute febrile disease annually, including more than 500,000 reported cases of DHF/DSS. Currently, dengue is endemic in 112 countries.
    • Race ; Age and Sex Ethnicity is nonspecific All ages are susceptible.
    • Both sexes have the same incidence, however, fewer cases have been reported more in men than in women.
    • Transmission o by mosquito vectors  Aedes aegypti in the sub- tropical and tropical Americas  Aedes albopictus in Asia
    • Aedes Aegypti the Dengue Vector
    • Mortality/Morbidity • Treated DHF/DSS is associated with a 3% mortality rate. • Untreated DHF/DSS is associated with a 50% mortality rate.
    • Clinical Presentation
    •  Rash– petechial, diffuse erythematous or morbilliform  Hemorrhagic manifestations – epistaxis, petechiae, gum bleeding
    •  Leukopenia  Thrombocytopenia  Lymphadenopathy
    •  Breakbone fever  Infectioncan lead to DHF, resulting in renal failure and DSS
    • Treatment No vaccine available, treatment is supportive
    • Our hospital statistic
    • Range of Patie nts Age 21 - 34 Year Patient 10 30 50 Year
    • % Male Vs. %Female Patients 27% 73%
    • Positive IgM Vs. Nigative Patients Negative IgM Patients, 28% Positive IgM Patients, 72%
    • % Saudi Vs . Non Saudi w ith Pos itive IgM Non Saudi Saudi 49% 51%
    • 4 Months Patients Vs. Total Patients 11 60
    • %Male Vs. %Female with PositiveIgM Fe m ale 33% M ale 67%
    • Thank you